75 articles for L Lin
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs.
University of Nebraska Kearney
Schiff's base derivatives bearing nitroimidazole and quinoline nuclei: new class of anticancer agents and potential EGFR tyrosine kinase inhibitors.
Nanjing University
Design, synthesis and molecular modeling of pyrazole-quinoline-pyridine hybrids as a new class of antimicrobial and anticancer agents.
Nanjing University
Synthesis and activity of substituted heteroaromatics as positive allosteric modulators fora4ß2a5 nicotinic acetylcholine receptors.
The Scripps Research Institute
Discovery of XEN445: a potent and selective endothelial lipase inhibitor raises plasma HDL-cholesterol concentration in mice.
Xenon Pharmaceuticals
A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
Genentech
Design and synthesis of 1-aryl-5-anilinoindazoles as c-Jun N-terminal kinase inhibitors.
The Scripps Research Institute
Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.
The Scripps Research Institute
Amino acid derived quinazolines as Rock/PKA inhibitors.
Translational Research Institute
Small molecule amides as potent ROR-¿ selective modulators.
The Scripps Research Institute
Synthesis, cytotoxicity of new 4-arylidene curcumin analogues and their multi-functions in inhibition of both NF-¿B and Akt signalling.
Sun Yat-Sen University
Small molecule tertiary amines as agonists of the nuclear hormone receptor Rev-erba.
The Scripps Research Institute
Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists.
Scripps Florida
Synthesis and SAR of tetrahydroisoquinolines as Rev-erba agonists.
The Scripps Research Institute
Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
Merck Research Laboratories
Identification of diaryl ether-based ligands for estrogen-related receptora as potential antidiabetic agents.
Johnson & Johnson Pharmaceutical Research and Development
Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.
Translational Research Institute
Synthesis and cytotoxicity evaluation of biaryl-based chalcones and their potential in TNFa-induced nuclear factor-¿B activation inhibition.
Sun Yat-Sen University
Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).
The Scripps Research Institute
Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.
The Scripps Research Institute
Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).
The Scripps Research Institute
Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
Pfizer
A novel binding assay identifies high affinity ligands to the rosiglitazone binding site of mitoNEET.
Northeast Ohio Medical University
Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors.
The Scripps Research Institute
Synthesis and SAR of novel quinazolines as potent and brain-penetrant c-jun N-terminal kinase (JNK) inhibitors.
The Scripps Research Institute
Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors.
Translational Research Institute
Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.
The Scripps Research Institute
A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
Chinese Academy of Sciences
Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.
Translational Research Institute and Department of Molecular Therapeutics
Discovering novel quercetin-3-O-amino acid-esters as a new class of Src tyrosine kinase inhibitors.
Chinese Academy of Sciences
Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.
The Scripps Research Institute-Florida
A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.
National Center For Drug Screening
AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo.
Shanghai Institute of Materia Medica
Discovery of a Novel ASM Direct Inhibitor with a 1,5-Diphenyl-pyrazole Scaffold and Its Antidepressant Mechanism of Action.
China Pharmaceutical University
Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors.
Schering-Plough Research Institute
Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.
The Scripps Research Institute
Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach.
Incyte
An overview of aryl hydrocarbon receptor ligands in the Last two decades (2002-2022): A medicinal chemistry perspective.
China Pharmaceutical University
Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model.
Amgen
Discovery of novel 2,8-diazaspiro[4.5]decan-1-one derivatives as potent RIPK1 kinase inhibitors.
China Pharmaceutical University
Cyclic urea derivatives as potent NK1 selective antagonists. Part II: Effects of fluoro and benzylic methyl substitutions.
Schering-Plough Research Institute
Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2.
Incyte
Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents.
Sun Yat-Sen University
Identification of a 5-HT4 receptor antagonist clinical candidate through side-chain modification.
Roche Palo Alto
Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3.
Prelude Therapeutics
Use of Crystallography and Molecular Modeling for the Inhibition of the Botulinum Neurotoxin A Protease.
Scripps Research
The dual inhibition against the activity and expression of tyrosine phosphatase PRL-3 from a rhodanine derivative.
Shanxi University
The components and activities analysis of a novel anticoagulant candidate dHG-5.
University of Chinese Academy of Sciences
Irreversible inhibition of BoNT/A protease: proximity-driven reactivity contingent upon a bifunctional approach.
The Scripps Research Institute
LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates.
University of California San Francisco
Structure-Activity Relationship and Biological Investigation of SR18292 (
The Scripps Research Institute
Structure-activity relationships of oxime neurokinin antagonists: oxime modifications.
Schering-Plough Research Institute
Synthesis and structure-activity relationships of oxime neurokinin antagonists: discovery of potent arylamides.
Schering-Plough Research Institute
Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.
Boston University School of Medicine
Quantitative Proteomics Reveals Cellular Off-Targets of a DDR1 Inhibitor.
Jinan University
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
Medichem Research
Design, Synthesis, and Biological Evaluation of Indole Biphenylcarboxylic Acids as PPARγ Antagonists.
The Scripps Research Institute
Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
The Ohio State University
Synthesis and SAR of novel isoxazoles as potent c-jun N-terminal kinase (JNK) inhibitors.
The Scripps Research Institute
In vivo and in vitro studies on the neurotoxic potential of 6-hydroxydopamine analogs.
University of Oklahoma
Precise structures of fucosylated glycosaminoglycan and its oligosaccharides as novel intrinsic factor Xase inhibitors.
Chinese Academy of Sciences
3-CYCLOAMINO-INDOLE COMPOUNDS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
Mindset Pharma
SUBSTITUTED BENZO[f][l ,2,4JTRIAZOL0[4,3-a][l ,4JDIAZEPINES AS GABA A GAMMA! POSITIVE ALLOSTERIC MODULATORS
Hoffmann-La Roche
COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA
Stealth Biotherapeutics
Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
Schering-Plough Research Institute